4.2 Article

Cap disease due to mutation of the beta-tropomyosin gene (TPM2)

Journal

NEUROMUSCULAR DISORDERS
Volume 19, Issue 5, Pages 348-351

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.nmd.2009.03.003

Keywords

Cap myopathy; Tropomyosin; Congenital myopathy; Cardiomyopathy; Congenital fibre type disproportion; TPM2; Beta-tropomyosin

Funding

  1. National Health and Medical Research Council, Australia [206529, 403941]
  2. Muscular Dystrophy Association of New South Wales (N.C. and K.N.).

Ask authors/readers for more resources

Cap disease or cap myopathy is a form of congenital myopathy in which peripheral, well-demarcated 'caps' of disorganised thin filaments are seen in muscle fibres. Mutation of the TPM2 gene, that encodes beta-tropomyosin, is the first reported genetic cause. In this paper, we describe a further case of cap disease due to a mutation in TPM2, confirming the importance of this genetic association. This is the first report of cardiac dysfunction due to a mutation in TPM2. Our patient has an identical TPM2 mutation to the first genetically diagnosed cap disease patient, a de novo heterozygous three base pair deletion that removes glutamic acid 139 from the centre of beta-tropomyosin (p.E139del). 2D-gel electrophoresis studies show that the shortened mutant protein incorporates into sarcomeric structures, where it likely imposes a dominant-negative effect to cause muscle weakness. (C) 2009 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available